Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61506 | 0.97 | SLC6A5 (0.58) | SLC6A5DRD4HIF1AEPAS1DRD2 | |
| SCHEMBL62031 | 0.89 | SLC6A5 (0.60) | SLC6A5DRD4HIF1AEPAS1DRD2 | |
| SCHEMBL15473187 | 0.86 | SLC6A5 (0.56) | SLC6A5DRD4HIF1AEPAS1DRD2 | |
| SCHEMBL61321 | 0.81 | DRD4 (0.59) | SLC6A5DRD4DRD2MEN1KMT2A | |
| SCHEMBL61841 | 0.80 | SLC6A5 (0.61) | SLC6A5DRD4HIF1AEPAS1DRD2 | |
| SCHEMBL69676 | 0.76 | DRD4 (0.51) | SLC6A5DRD4DRD2MEN1KMT2A | |
| SCHEMBL61238 | 0.76 | DRD4 (0.53) | SLC6A5DRD4DRD2 | |
| SCHEMBL61826 | 0.73 | DRD4 (0.61) | SLC6A5DRD4DRD2MEN1KMT2A | |
| SCHEMBL62237 | 0.73 | DRD4 (0.76) | SLC6A5DRD4HIF1AEPAS1MEN1 | |
| SCHEMBL61207 | 0.73 | HDAC1 (0.56) | SLC6A5DRD4HIF1AEPAS1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231666-B1 | Carboxamide, sulfonamide and amine compounds for metabolic disorders | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8895578-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8557822-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | SLC6A5 4540/4885DRD4 2946/4885HIF1A 711/4885 |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | SLC6A5 4540/4885DRD4 2946/4885HIF1A 711/4885 |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | SLC6A5 4540/4885DRD4 2946/4885HIF1A 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.